-
1
-
-
4544254807
-
The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years?
-
Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172(4 Pt 1):1297-1301.
-
(2004)
J Urol
, vol.172
, Issue.4 PART 1
, pp. 1297-1301
-
-
Stamey, T.A.1
Caldwell, M.2
McNeal, J.E.3
Nolley, R.4
Hemenez, M.5
Downs, J.6
-
2
-
-
0242692717
-
CaPSURE. Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE)
-
Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR; CaPSURE. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003;170(6 Pt 2):S21-S25.
-
(2003)
J Urol
, vol.170
, Issue.6 PART 2
-
-
Cooperberg, M.R.1
Lubeck, D.P.2
Mehta, S.S.3
Carroll, P.R.4
-
3
-
-
80255138171
-
High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy
-
Fang LC, Merrick GS, Butler WM, Galbreath RW, Murray BC, Reed JL, et al. High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2011;81:992-996.
-
(2011)
Int J Radiat Oncol Biol Phys
, vol.81
, pp. 992-996
-
-
Fang, L.C.1
Merrick, G.S.2
Butler, W.M.3
Galbreath, R.W.4
Murray, B.C.5
Reed, J.L.6
-
4
-
-
80053599473
-
Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer
-
Dibiase SJ, Hussain A, Kataria R, Amin P, Bassi S, Dawson N, et al. Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2011;81:732-736.
-
(2011)
Int J Radiat Oncol Biol Phys
, vol.81
, pp. 732-736
-
-
Dibiase, S.J.1
Hussain, A.2
Kataria, R.3
Amin, P.4
Bassi, S.5
Dawson, N.6
-
5
-
-
0037072063
-
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial
-
Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-106.
-
(2002)
Lancet
, vol.360
, pp. 103-106
-
-
Bolla, M.1
Collette, L.2
Blank, L.3
Warde, P.4
Dubois, J.B.5
Mirimanoff, R.O.6
-
6
-
-
45149105820
-
Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer
-
Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2497-2504.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2497-2504
-
-
Horwitz, E.M.1
Bae, K.2
Hanks, G.E.3
Porter, A.4
Grignon, D.J.5
Brereton, H.D.6
-
7
-
-
0032538069
-
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
-
D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.
-
(1998)
JAMA
, vol.280
, pp. 969-974
-
-
D'Amico, A.V.1
Whittington, R.2
Malkowicz, S.B.3
Schultz, D.4
Blank, K.5
Broderick, G.A.6
-
8
-
-
44649141981
-
Radical prostatectomy for high-risk prostate cancer
-
Yossepowitch O, Eastham JA. Radical prostatectomy for high-risk prostate cancer. World J Urol 2008;26:219-224.
-
(2008)
World J Urol
, vol.26
, pp. 219-224
-
-
Yossepowitch, O.1
Eastham, J.A.2
-
9
-
-
41149141496
-
Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy
-
Yossepowitch O, Eggener SE, Serio AM, Carver BS, Bianco FJ Jr, Scardino PT, et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 2008;53:950-959.
-
(2008)
Eur Urol
, vol.53
, pp. 950-959
-
-
Yossepowitch, O.1
Eggener, S.E.2
Serio, A.M.3
Carver, B.S.4
Bianco Jr., F.J.5
Scardino, P.T.6
-
10
-
-
33646948287
-
Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy
-
Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006;65:669-677.
-
(2006)
Int J Radiat Oncol Biol Phys
, vol.65
, pp. 669-677
-
-
Merrick, G.S.1
Butler, W.M.2
Wallner, K.E.3
Galbreath, R.W.4
Allen, Z.A.5
Adamovich, E.6
-
11
-
-
33845599085
-
15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience
-
Sylvester JE, Grimm PD, Blasko JC, Millar J, Orio PF 3rd, Skoglund S, et al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 2007;67:57-64.
-
(2007)
Int J Radiat Oncol Biol Phys
, vol.67
, pp. 57-64
-
-
Sylvester, J.E.1
Grimm, P.D.2
Blasko, J.C.3
Millar, J.4
Orio III, P.F.5
Skoglund, S.6
-
12
-
-
33745184874
-
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
-
Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-974.
-
(2006)
Int J Radiat Oncol Biol Phys
, vol.65
, pp. 965-974
-
-
Roach III, M.1
Hanks, G.2
Thames Jr., H.3
Schellhammer, P.4
Shipley, W.U.5
Sokol, G.H.6
-
13
-
-
0032753788
-
Permanent prostate seed implant brachytherapy: Report of the American Association of Physicists in Medicine Task Group No. 64
-
Yu Y, Anderson LL, Li Z, Mellenberg DE, Nath R, Schell MC, et al. Permanent prostate seed implant brachytherapy: report of the American Association of Physicists in Medicine Task Group No. 64. Med Phys 1999;26:2054-2076.
-
(1999)
Med Phys
, vol.26
, pp. 2054-2076
-
-
Yu, Y.1
Anderson, L.L.2
Li, Z.3
Mellenberg, D.E.4
Nath, R.5
Schell, M.C.6
-
14
-
-
34047126239
-
Tumour and target volumes in permanent prostate brachytherapy: A supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy
-
Salembier C, Lavagnini P, Nickers P, Mangili P, Rijnders A, Polo A, et al. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 2007;83:3-10.
-
(2007)
Radiother Oncol
, vol.83
, pp. 3-10
-
-
Salembier, C.1
Lavagnini, P.2
Nickers, P.3
Mangili, P.4
Rijnders, A.5
Polo, A.6
-
15
-
-
33846617687
-
Initial analysis of Pro-Qura: A multi-institutional database of prostate brachytherapy dosimetry
-
Merrick GS, Grimm PD, Sylvester J, Blasko JC, Butler WM, Allen ZA, et al. Initial analysis of Pro-Qura: a multi-institutional database of prostate brachytherapy dosimetry. Brachytherapy 2007; 6:9-15.
-
(2007)
Brachytherapy
, vol.6
, pp. 9-15
-
-
Merrick, G.S.1
Grimm, P.D.2
Sylvester, J.3
Blasko, J.C.4
Butler, W.M.5
Allen, Z.A.6
-
16
-
-
0028969271
-
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)
-
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-1346.
-
(1995)
Int J Radiat Oncol Biol Phys
, vol.31
, pp. 1341-1346
-
-
Cox, J.D.1
Stetz, J.2
Pajak, T.F.3
-
17
-
-
33750338077
-
Casematched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer
-
Fletcher SG, Mills SE, Smolkin ME, Theodorescu D. Casematched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2006;66:1092-1099.
-
(2006)
Int J Radiat Oncol Biol Phys
, vol.66
, pp. 1092-1099
-
-
Fletcher, S.G.1
Mills, S.E.2
Smolkin, M.E.3
Theodorescu, D.4
-
18
-
-
0034177612
-
Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation
-
Stokes SH. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Biol Phys 2000;47:129-136.
-
(2000)
Int J Radiat Oncol Biol Phys
, vol.47
, pp. 129-136
-
-
Stokes, S.H.1
-
19
-
-
0034661749
-
Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer
-
Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner KE. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000;47: 1261-1266.
-
(2000)
Int J Radiat Oncol Biol Phys
, vol.47
, pp. 1261-1266
-
-
Zelefsky, M.J.1
Hollister, T.2
Raben, A.3
Matthews, S.4
Wallner, K.E.5
-
20
-
-
34547111263
-
Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features
-
Dattoli M, Wallner K, True L, Cash J, Sorace R. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer 2007;110:551-555.
-
(2007)
Cancer
, vol.110
, pp. 551-555
-
-
Dattoli, M.1
Wallner, K.2
True, L.3
Cash, J.4
Sorace, R.5
-
21
-
-
58149327450
-
Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy
-
Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009;73:341-346.
-
(2009)
Int J Radiat Oncol Biol Phys
, vol.73
, pp. 341-346
-
-
Stone, N.N.1
Potters, L.2
Davis, B.J.3
Ciezki, J.P.4
Zelefsky, M.J.5
Roach, M.6
-
22
-
-
77957354591
-
Localized prostate cancer with intermediate- or high-risk features treated with combined external beam radiotherapy and io dine-125 seed brachytherapy
-
da Silva Franca CA, Vieira SL, Carvalho AC, Bernabé AJ, Penna AB. Localized prostate cancer with intermediate- or high-risk features treated with combined external beam radiotherapy and io dine-125 seed brachytherapy. Brachytherapy 2010;9:307-312.
-
(2010)
Brachytherapy
, vol.9
, pp. 307-312
-
-
da Silva, F.C.A.1
Vieira, S.L.2
Carvalho, A.C.3
Bernabé, A.J.4
Penna, A.B.5
-
23
-
-
77954878125
-
Contemporary treatment of high-risk localized prostate cancer
-
Tareen B, Kimmel J, Huang WC. Contemporary treatment of high-risk localized prostate cancer. Expert Rev Anticancer Ther 2010;10:1069-1076.
-
(2010)
Expert Rev Anticancer Ther
, vol.10
, pp. 1069-1076
-
-
Tareen, B.1
Kimmel, J.2
Huang, W.C.3
-
24
-
-
79953716767
-
What are the outcomes of radical prostatectomy for high-risk prostate cancer?
-
Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology 2010;76:710-714.
-
(2010)
Urology
, vol.76
, pp. 710-714
-
-
Loeb, S.1
Schaeffer, E.M.2
Trock, B.J.3
Epstein, J.I.4
Humphreys, E.B.5
Walsh, P.C.6
-
25
-
-
0032054704
-
A dose-response study for I-125 prostate implants
-
Stock RG, Stone NN, Tabert A, Iannuzzi C, DeWyngaert JK. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 1998;41:101-108.
-
(1998)
Int J Radiat Oncol Biol Phys
, vol.41
, pp. 101-108
-
-
Stock, R.G.1
Stone, N.N.2
Tabert, A.3
Iannuzzi, C.4
Dewyngaert, J.K.5
-
26
-
-
37049020446
-
(125)I monotherapy using D90 implant doses of 180 Gy or greater
-
Kao J, Stone NN, Lavaf A, Dumane V, Cesaretti JA, Stock RG. (125)I monotherapy using D90 implant doses of 180 Gy or greater. Int J Radiat Oncol Biol Phys 2008;70:96-101.
-
(2008)
Int J Radiat Oncol Biol Phys
, vol.70
, pp. 96-101
-
-
Kao, J.1
Stone, N.N.2
Lavaf, A.3
Dumane, V.4
Cesaretti, J.A.5
Stock, R.G.6
-
27
-
-
65449131937
-
Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy
-
Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2009;75:16-22.
-
(2009)
Int J Radiat Oncol Biol Phys
, vol.75
, pp. 16-22
-
-
Ho, A.Y.1
Burri, R.J.2
Cesaretti, J.A.3
Stone, N.N.4
Stock, R.G.5
-
28
-
-
58849157900
-
Long-term health-related quality-of-life outcomes after permanent prostate brachytherapy
-
Schafer JW, Welzel G, Trojan L, Eppler N, Harrer K, Michel MS, et al. Long-term health-related quality-of-life outcomes after permanent prostate brachytherapy. Onkologie 2008;31:599-603.
-
(2008)
Onkologie
, vol.31
, pp. 599-603
-
-
Schafer, J.W.1
Welzel, G.2
Trojan, L.3
Eppler, N.4
Harrer, K.5
Michel, M.S.6
-
29
-
-
65449152540
-
Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer
-
Koontz BF, Chino J, Lee WR, Hahn CA, Buckley N, Huang S, et al. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer. Brachytherapy 2009;8:191-196.
-
(2009)
Brachytherapy
, vol.8
, pp. 191-196
-
-
Koontz, B.F.1
Chino, J.2
Lee, W.R.3
Hahn, C.A.4
Buckley, N.5
Huang, S.6
|